IWA
CRL icon

IBEX Wealth Advisors’s Charles River Laboratories CRL Stock Holding History

IBEX Wealth Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,022
Closed -$385K – 182
2021
Q4 		$385K Sell
1,022
-10,167
-91% -$3.95M 0.07% 136
2021
Q3 		$4.62M Buy
11,189
+316
+3% +$131K 0.89% 37
2021
Q2 		$4.02M Buy
10,873
+487
+5% +$163K 0.8% 49
2021
Q1 		$3.01M Buy
+10,386
New +$2.89M 0.74% 62

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

IBEX Wealth Advisors's CRL Position: Q1 2022 in Review

IBEX Wealth Advisors sold out of Charles River Laboratories (CRL) in Q1 2022, closing a stake of 1,022 shares — an estimated $385K sold.

IBEX Wealth Advisors first reported a position in CRL in Q1 2021 and held it in 4 quarters. The position peaked at $4.62M in Q3 2021. 644 funds tracked by Wall St. Rank hold CRL as of Q1 2022.

  • IBEX Wealth Advisors reported no remaining Charles River Laboratories position as of Q1 2022 after selling out during the quarter.
  • IBEX Wealth Advisors sold 1,022 Charles River Laboratories shares in Q1 2022, an estimated $385K.
  • IBEX Wealth Advisors first reported a position in Charles River Laboratories in Q1 2021 and held it in 4 quarters.
  • IBEX Wealth Advisors's Charles River Laboratories position peaked at $4.62M in Q3 2021.
  • 644 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2022.

Based on IBEX Wealth Advisors's 13F filing for Q1 2022, filed 16 May 2022.